grant
A multiomic analysis of HER2/ERBB2 in African American men with prostate cancer
Organization MOREHOUSE SCHOOL OF MEDICINELocation ATLANTA, UNITED STATESPosted 7 Jul 1997Deadline 31 Mar 2028
NIHUS FederalResearch GrantFY20253-D analysis3-dimensional analysis3D analysis3D cell culture3D cultureAfrican AmericanAfrican ancestryAfrican descentAfro AmericanAfroamericanAlabamaAmerican maleAmerican manAmerican menAndrogen SuppressionAndrogenic AgentsAndrogenic CompoundsAndrogensAreaAssayBioassayBiological AssayBlood SampleBlood SerumBlood specimenCaliforniaCancer PatientCancer TreatmentCell BodyCell Communication and SignalingCell DeathCell FunctionCell IsolationCell LineCell PhysiologyCell ProcessCell SegregationCell SeparationCell Separation TechnologyCell SignalingCellLineCellsCellular FunctionCellular PhysiologyCellular ProcessCenter for Translational Science ActivitiesChIP assayCitiesClinicalClinical TrialsCollaborationsComprehensive Cancer CenterDNA MethylationDiagnosisDiseaseDisorderDistant CancerDistant MetastasisEGF ReceptorEGFRERBB ProteinERBB2ERBB2 geneEndocrine Gland SecretionEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor KinaseEpidermal Growth Factor Receptor Protein-Tyrosine KinaseEpidermal Growth Factor-Urogastrone ReceptorsEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEuropeanEvaluationEventFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFoundationsFutureGenesGeneticGenetic DiversityGenetic VariationGleason GradeGleason Grade for Prostate CancerGleason ScoreGleason Score for Prostate CancerGleason SumGleason-SCGoalsHER -2HER-2HER1HER2HER2 GenesHER2/neuHealthHormonesHumanIRBIRBsImmunoblottingImmunohistochemistryImmunohistochemistry Cell/TissueImmunohistochemistry Staining MethodImmunooncologyInstitutional Review BoardsIntracellular Communication and SignalingInvestigationMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant neoplasm of prostateMalignant prostatic tumorMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic Prostate CancerMetastatic TumorModern ManMolecularMorehouse Sch of MedicineMorehouse School of MedMorehouse School of MedicineNEU OncogeneNEU proteinNeoplasm Circulating CellsNeoplasm MetastasisOncogene ErbB2OutcomePSA levelPSA valuePatientsPrognosisProspective StudiesProstate CAProstate CancerProstate Carcinoma MetastaticProstate malignancyProstatic ParenchymaProstatic TissueProteinsProteomicsRNA SeqRNA analysisRNA sequencingRNAseqRaceRacesRelapseResearch ProposalsRoleSNP genotypingSamplingSecondary NeoplasmSecondary TumorSerumSignal PathwaySignal TransductionSignal Transduction SystemsSignalingStem Cell likeStrains Cell LinesSubcellular ProcessTGF-alpha ReceptorTKR1Therapeutic AndrogenTherapeutic HormoneThree-dimensional analysisTissue SampleTransfectionTransforming Growth Factor alpha ReceptorTreatment outcomeTumor BiologyTumor TissueU.S. MalesUS MenUS maleUnited StatesUniversitiesUrogastrone ReceptorValidationVariantVariationWest AfricanWestern BlottingWestern Immunoblottingadvanced prostate cancerandrogen ablation therapyandrogen blockade therapyandrogen deprivation therapyandrogen deprivation treatmentanti-cancer therapybiological signal transductionc-erbB-1c-erbB-1 Proteinc-erbB-2c-erbB-2 Genesc-erbB-2 Proto-Oncogenescancer metastasiscancer therapycancer-directed therapycell sortingchemotherapychromatin immunoprecipitationcirculating neoplastic cellcirculating tumor cellcultured cell linedeath riskdeterminants of therapy resistancedeterminants of treatment resistancedifferential expressiondifferentially expresseddisparate effectdisparate impactdisparate resultdisparity in healthepigeneticallyerbB-1erbB-1 Proto-Oncogene ProteinerbB-2 GeneserbBlflow cytophotometrygenome scalegenome wide methylationgenome-widegenomewidegenomewide methylationglobal methylationhealth disparityherstatinhigh riskhistone modificationimmune-oncologyimmuno oncologyimmunology oncologyinequitable effectinequitable impactinequitable outcomeliquid biopsymales in Americamales in the U.S.males in the USmales in the USAmales in the United Statesmenmen in Americamen in the U.S.men in the USmen in the USAmen in the United Statesmigrationmonolayermortalitymortality riskmultiomicsmultiple omicsnecrocytosisneu Genesoncoimmunologyoutcome disparitiesoutcome inequalityoutcome inequityoverexpressoverexpressionpanomicsperipheral bloodprecision medicineprecision-based medicinepredictors of therapy resistancepredictors of treatment resistanceprogenitor capacityprogenitor cell likeprogenitor-likeprostate cancer cell lineprostate cancer progressionprostate specific antigen levelprostate specific antigen valueprotein blottingprotein expressionproteomic signatureproto-oncogene protein c-erbB-1public data basepublic databasepublicly accessible data basepublicly accessible databasepublicly available data basepublicly available databaseracialracial backgroundracial diversityracial originracially diverserecruitresearch studyresistance to therapyresistant to therapyresponse to therapyresponse to treatmentsingle cell genomicssingle nucleotide polymorphism genotypingsocial rolestem cell characteristicsstem-likestemnesssurvival outcometaxanetherapeutic resistancetherapeutic responsetherapy resistanttherapy responsethree dimensional cell culturetranscriptional differencestranscriptome sequencingtranscriptomic sequencingtranscriptomicstranslational research centertranslational sciences centertreatment resistancetreatment responsetreatment responsivenesstumortumor cell metastasisunequal effectunequal impactunequal outcomevalidations
Description preview
Modified Project Summary/Abstract Section
There is no cure for metastatic prostate cancer (PCa), and about 1 in 41 men in the United States (U.S.) will die of the disease. Since African American (AA) men are most likely to be diagnosed with metastatic PCa, the expansion of research studies that thoroughly evaluate the molecular mechanisms which…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click